DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application
| Autor: | Fabiola Reginato, Sandrine Comparsi Wagner, Rafael Linden, Natalia Vieira, Vanessa Suñé Mattevi, Suziane Raymundo, Marina Venzon Antunes, Renata Leite, Laura Fogliatto, Marcelo Capra |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Adolescent Clinical Biochemistry Pharmacology Hematocrit Analytical Chemistry Young Adult Tandem Mass Spectrometry Leukemia Myelogenous Chronic BCR-ABL Positive Surveys and Questionnaires Blood plasma medicine Humans General Pharmacology Toxicology and Pharmaceutics Child Chromatography High Pressure Liquid Aged Aged 80 and over medicine.diagnostic_test business.industry Reproducibility of Results Imatinib General Medicine Middle Aged Patient Acceptance of Health Care Method development Medical Laboratory Technology Imatinib mesylate Therapeutic drug monitoring Plasma concentration Imatinib Mesylate Female Dried Blood Spot Testing Drug Monitoring business medicine.drug |
| Zdroj: | Bioanalysis. 7(16) |
| ISSN: | 1757-6199 |
| Popis: | Background: Imatinib (IM) is widely used in treatment of chronic myeloid leukemia with target trough plasma concentrations above 1000 ng ml-1. DBS can increase access to IM therapeutic drug monitoring. Results: IM was measured in the range 50–4000 ng ml-1 by UHPLC–MS/MS using one 6 mm DBS in a fully validated method. IM was stable at DBS maintained at 40°C for 36 days. Plasma and DBS concentrations were highly correlated (r > 0.96). The use of a IM concentration target of 765 ng ml-1 in DBS identified 93% of patients with plasma concentration below 1000 ng ml-1. Conclusion: IM can be measured in DBS using UHPLC–MS/MS with results comparable to those obtained in blood plasma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|